OCUL Stock Overview
A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
FDA Approval And Adjusted Trials Will Expand Treatment Options
Ocular Therapeutix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.00 |
| 52 Week High | US$11.78 |
| 52 Week Low | US$4.06 |
| Beta | 1.49 |
| 1 Month Change | 7.69% |
| 3 Month Change | -20.09% |
| 1 Year Change | -17.36% |
| 3 Year Change | 42.57% |
| 5 Year Change | 29.15% |
| Change since IPO | -46.77% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S
Mar 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
Mar 24 AXPAXLI's FDA amendment enables better dosing schedules, boosting market penetration and revenue through superior treatment durability.Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Mar 06Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet?
Feb 25Recent updates
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S
Mar 25FDA Approval And Adjusted Trials Will Expand Treatment Options
Mar 24 AXPAXLI's FDA amendment enables better dosing schedules, boosting market penetration and revenue through superior treatment durability.Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Mar 06Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet?
Feb 25Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Shareholder Returns
| OCUL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.7% | -3.1% | -5.6% |
| 1Y | -17.4% | -4.3% | 3.3% |
Return vs Industry: OCUL underperformed the US Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: OCUL underperformed the US Market which returned 8.4% over the past year.
Price Volatility
| OCUL volatility | |
|---|---|
| OCUL Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: OCUL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OCUL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 274 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
Ocular Therapeutix, Inc. Fundamentals Summary
| OCUL fundamental statistics | |
|---|---|
| Market cap | US$1.17b |
| Earnings (TTM) | -US$193.51m |
| Revenue (TTM) | US$63.72m |
17.5x
P/S Ratio-5.8x
P/E RatioIs OCUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCUL income statement (TTM) | |
|---|---|
| Revenue | US$63.72m |
| Cost of Revenue | US$133.26m |
| Gross Profit | -US$69.54m |
| Other Expenses | US$123.97m |
| Earnings | -US$193.51m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | -109.13% |
| Net Profit Margin | -303.67% |
| Debt/Equity Ratio | 21.7% |
How did OCUL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 04:19 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocular Therapeutix, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Anita Dushyanth | Berenberg |
| Tazeen Ahmad | BofA Global Research |